Pioneering the trail of cancer immunotherapy

Abstract

The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exciting new developments in cancer immunotherapy, it is critically important to effectively guide new immune-based advances from bench to bedside to improve outcomes of patients with cancer. iSBTc/SITC with its dedicated leadership (past and present) provides this guidance through its Annual Meeting and associated programs. This year the society celebrated its 25th Anniversary in Hyatt Regency Washington on Capitol Hill (Washington DC, USA), with educational offerings from 30 September to 4 October 2010.

Acknowledgements

The authors kindly acknowledge the program organizers for their dedication and effort to make the Annual Meeting and associated programs a success. The Harry J Lloyd Charitable Trust melanoma research award is acknowledged for supporting Beatrix Kotlan’s attendance and presentation.

Financial & competing interests disclosure

James M Balwit is employed as Director of Scientific Communications for the Society for Immunotherapy of Cancer, formerly the International Society for Biological Therapy of Cancer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.